The Role of Bacillus Calmette-Guérin in the Treatment of Non–Muscle-Invasive Bladder Cancer
- 31 March 2010
- journal article
- review article
- Published by Elsevier BV in European Urology
- Vol. 57 (3), 410-429
- https://doi.org/10.1016/j.eururo.2009.11.023
Abstract
No abstract availableKeywords
This publication has 86 references indexed in Scilit:
- Retinoblastoma protein expression predicts response to bacillus Calmette-Guérin immunotherapy in patients with T1G3 bladder cancerUrologic Oncology, 2010
- Methodology of Superficial Bladder Cancer Trials: Objective Evaluation of Treatment – The Need for StandardizationUrologia Internationalis, 2009
- An Individual Patient Data Meta-Analysis of the Long-Term Outcome of Randomised Studies Comparing Intravesical Mitomycin C versus Bacillus Calmette-Guérin for Non–Muscle-Invasive Bladder CancerEuropean Urology, 2009
- Can Early Single Dose Instillation of Epirubicin Improve Bacillus Calmette-Guerin Efficacy in Patients With Nonmuscle Invasive High Risk Bladder Cancer? Results From a Prospective, Randomized, Double-Blind Controlled StudyJournal of Urology, 2008
- Does ofloxacin protect against BCG-related toxic effects in patients with bladder cancer?Nature Reviews Endocrinology, 2007
- Intravesical bacillus Calmette‐Guèrin therapy: experience with a reduced dwell‐time in patients with pronounced side‐effectsBJU International, 2005
- Prognostic Factors in Stage T1 Grade 3 Bladder Cancer Survival: The Role of G1–S Modulators (p53, p21Waf1, p27kip1, Cyclin D1, and Cyclin D3) and Proliferation Index (ki67-MIB1)European Urology, 2004
- Use of BCG in Immunotherapy of Superficial Bladder Cancer: Multicentric Investigation on Safety and ComplianceUroOncology, 2003
- Defining Bacillus Calmette-Guerin Refractory Superficial Bladder TumorsJournal of Urology, 2003
- Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumour necrosis factor during intravesical immunotherapy with bacillus Calmette-Guérin in superficial bladder cancerCancer Immunology, Immunotherapy, 1992